Post Profile

Bristol drug flop opens big cancer opportunity: AstraZeneca CEO

COPENHAGEN (Reuters) - The failure of Bristol-Myers Squibb's blockbuster Opdivo immunotherapy in previously untreated lung cancer patients has opened up the market for AstraZeneca, its chief executive believes.
read more


Related Posts

Lung cancer doctors eye Merck's Keytruda over Bristol's Opdivo

Health : Reuters: Health

(Reuters) - Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges...

No silver lining in failed Bristol cancer drug trial

Health : Reuters: Health

COPENHAGEN (Reuters) - Bristol-Myers Squibb disappointed investors on Sunday as researchers detailed data for its Opdivo cancer immunotherapy, which was already known to have failed to do better than older chemotherapies in a closel...

Merck drug shines in lung cancer and also works with chemo

Health : Reuters: Health

COPENHAGEN (Reuters) - Merck & Co scored a double hit on Sunday with new clinical data showing its Keytruda immunotherapy offered big benefits in previously untreated lung cancer patients, either when given on its own or with chemot...

Bristol lung-cancer setback puts rival Merck drug in driver seat

Health : Reuters: Health

(Reuters) - New data is likely to prompt doctors to abandon Bristol-Myers Squibb's immunotherapy Opdivo in favor of Merck & Co's rival Keytruda in a large segment of the lucrative lung cancer market, analysts said on Monday. The res...

Denmark's Genmab looks to immunotherapy for cancer drug encore

Health : Reuters: Health

LONDON (Reuters) - Immunotherapy, which boosts the immune system to fight cancer, could be the next big opportunity for Genmab, potentially driving peak sales of its top-selling drug well past $10 billion a year, its chief executive...


Copyright © 2016 Regator, LLC